ArticleNeuro-oncology2026

Corrigendum to: The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.

No numbers read from the abstract.

Not cited yet